Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
And Then There Were Three: Woodcock Offers Another Explanation For Aduhelm’s Labeling Fiasco
Jul 15 2021
•
By
Sarah Karlin-Smith
Woodcock said it is standard policy for the Office of Neuroscience to issue broad labels. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Agency Leadership
More from Pink Sheet